---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-095373"
form_type: "8-K"
ticker: null
cik: "0001580063"
company_name: "BIORA THERAPEUTICS, INC."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:35:36.002719+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biora Therapeutics receives Nasdaq delisting notice for failing $50M assets/revenue requirement

## Summary
- Notice on April 4, 2023: Nasdaq Staff says BIOR no longer meets $50M total assets and $50M total revenue requirement.
- No immediate delisting; company has 45 days (by May 19, 2023) to submit plan to regain compliance.
- If plan accepted, Staff may grant up to 180 days (through Oct 2, 2023) to evidence compliance.
- If plan not accepted, Staff issues delisting determination; appeal to Hearings Panel stays delisting.
- Company evaluating options but no assurance of extension or regaining compliance.

## SEC filing metadata
- accession: 0001193125-23-095373
- form_type: 8-K
- cik: 0001580063
- company_name: BIORA THERAPEUTICS, INC.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580063/000119312523095373/0001193125-23-095373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580063/000119312523095373/d489128d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-095373
- JSON: https://secwatch.observer/filing/0001193125-23-095373.json
- Plain text: https://secwatch.observer/filing/0001193125-23-095373.txt

## Key facts
- Listing & Compliance Notices
  BIORA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(b)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5450(b)
  source text: April 4, 2023, Biora Therapeutics, Inc. (the “ Company ”) received formal notice from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company no longer satisfies the $50 million in total assets and $50 million in total revenue requirement for continued listing on The Nasdaq Global Market or the alternative criteria under Nasdaq Listing Rule 5450(b) (the “ Rule ”). The Staff’s notice has no immediate effect on the listing of the Company’s common stock, which the Company expects will continue to trade on Nasdaq in the normal course
  evidence_url: https://www.sec.gov/Archives/edgar/data/1580063/000119312523095373/0001193125-23-095373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.